<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961453</url>
  </required_header>
  <id_info>
    <org_study_id>01442</org_study_id>
    <nct_id>NCT01961453</nct_id>
  </id_info>
  <brief_title>Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function</brief_title>
  <acronym>ISMN</acronym>
  <official_title>Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporal Michael J. Crescenz VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporal Michael J. Crescenz VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test whether treatment with isosorbide mononitrate&#xD;
      will improve left ventricular hypertrophy (&quot;thickening&quot;) which puts people at risk for&#xD;
      developing heart failure. Once it develops, heart failure is a very serious condition and&#xD;
      thus it is important to find ways to prevent it from happening. The investigators have&#xD;
      reasons to believe that dilating the blood vessels with this specific medication will improve&#xD;
      the thickening of the heart, which increases the risk of heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding&#xD;
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular mass</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in extracellular volume fraction</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak myocardial systolic longitudinal strain measured by MRI</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak early diastolic intraventricular pressure gradient measured by MRI</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in late systolic hypertension derived from pulse wave analysis</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Isosorbide Mononitrate, sustained release</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule of placebo administered once daily at 8 AM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate, sustained release</intervention_name>
    <description>60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2</description>
    <arm_group_label>Isosorbide Mononitrate, sustained release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>One capsule of placebo administered once daily at 8 am.</description>
    <arm_group_label>Placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Systolic blood pressure &gt;140 mmHg, diastolic blood pressure &gt; 90 mmHg.&#xD;
&#xD;
          -  An elevated left ventricular mass index (defined as &gt;60 g/m1.7 in women and 80 g/m1.7&#xD;
             in men) OR LV posterior wall thickness &gt;1.4 cm documented in a clinically indicated&#xD;
             echocardiographic examination or magnetic resonance imaging scan within the previous&#xD;
             12 months.&#xD;
&#xD;
          -  Stable medical therapy as defined by: (1)No addition or removal of ACE inhibitors,&#xD;
             angiotensin receptor blockers, beta-blockers, or calcium channel blockers for 30 days.&#xD;
             (2)No change in dosage of ACE, angiotensin-receptor blocker, beta-blockers or&#xD;
             calcium-channel blockers s of more than 100% for 30 days.&#xD;
&#xD;
          -  Current therapy with an ACE inhibitor, hydralazine or a statin, all of which have been&#xD;
             shown to reduce nitrate tolerance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rhythm other than sinus rhythm (i.e., atrial fibrillation).&#xD;
&#xD;
          -  Non-cardiac condition limiting life expectancy to less than one year, per physician&#xD;
             judgment.&#xD;
&#xD;
          -  Current or anticipated future need for nitrate therapy.&#xD;
&#xD;
          -  Valve disease (&gt; mild aortic or mitral stenosis; &gt; moderate aortic or mitral&#xD;
             regurgitation).&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid).&#xD;
&#xD;
          -  Pericardial disease.&#xD;
&#xD;
          -  Primary pulmonary arteriopathy.&#xD;
&#xD;
          -  Have experienced a myocardial infarction or unstable angina, or have undergone&#xD;
             percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass&#xD;
             grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at&#xD;
             the time of consent.&#xD;
&#xD;
          -  Resting heart rate (HR) &gt; 100 bpm.&#xD;
&#xD;
          -  A reduced LV ejection fraction (EF&lt;50%).&#xD;
&#xD;
          -  Known severe liver disease (AST &gt; 3x normal, alkaline phosphatase or bilirubin &gt; 2x&#xD;
             normal).&#xD;
&#xD;
          -  Patients with a clinically indicated stress test demonstrating significant ischemia&#xD;
             within a year of enrollment which was not followed by percutaneous or surgical&#xD;
             revascularization.&#xD;
&#xD;
          -  Allergy to isosorbide mononitrate.&#xD;
&#xD;
          -  Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardenafil or&#xD;
             tadalafil, since the combination of nitrates and phosphodiesterase inhibitors can&#xD;
             result in severe hypotension.&#xD;
&#xD;
          -  Therapy with rosiglitazone, since this combination is not recommended based on&#xD;
             epidemiologic data suggesting that it may increase the risk of myocardial ischemia.&#xD;
&#xD;
          -  Current pregnancy or a positive urine pregnancy test. Women who become pregnant during&#xD;
             the study will be discontinued from the trial.&#xD;
&#xD;
          -  Contraindications to a cardiac MRI: (i) Central nervous system aneurysm clips; (ii)&#xD;
             Implanted neural stimulators; (iii) Implanted cardiac pacemaker or defibrillator; (iv)&#xD;
             Cochlear implant; (v) Ocular foreign body (e.g. metal shavings); (vi) Other implanted&#xD;
             medical devices: (e.g. drug infusion ports); (vii) Insulin pump; (viii) Metal shrapnel&#xD;
             or bullet; (ix) Claustrophobia; (x) Extreme obesity rendering the patient unable to&#xD;
             fit into narrow-bore scanners; (xi) Unwillingness of the patient to undergo a cardiac&#xD;
             MRI. All patients with metallic implants will be individually evaluated prior to MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio A Chirinos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Philadelphia VA Medical Center &amp; University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician. 2003 Dec 15;68(12):2393-8. Review.</citation>
    <PMID>14705758</PMID>
  </reference>
  <reference>
    <citation>Li H, Wang SX. Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate. J Nephrol. 2011 Mar-Apr;24(2):236-45.</citation>
    <PMID>21240870</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Isosorbide Mononitrate</keyword>
  <keyword>Myocardial fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

